Not finding it? Sign in to also search OpenAlex live.
-
Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
Hans Jürgen Salwender, Michael Hundemer, Uta Bertsch, Ema Požek, Axel Benner, Roland R. Fenk, +27 more
1citations -
Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial
Sonja Zweegman, Thierry T.F. Facon, Vânia Hungria, Nizar Jacques Bahlis, Christopher Paul Venner, Marc Justin Braunstein, +22 more
13citations -
Firstline Treatment with Ruxolitinib Versus Best Available Therapy in Patients with Polycythemia Vera: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)
Steffen Koschmieder, Susanne Isfort, Lino Lars Teichmann, Philippe Schafhausen, Florian Heinrich Heidel, Andreas Hochhaus, +18 more
4citations -
Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial
Hartmut Goldschmidt, Eva Nievergall, Roland R. Fenk, Uta Bertsch, Diana Tichy, Britta Besemer, +25 more
33citations -
Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance
Jacob P. Laubach, Jonathan L. Kaufman, Douglas Weston Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, +22 more
24citations -
Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study2020 Blood conference-abstract Biochemistry, Genetics and Molecular Biology Amyloidosis: Diagnosis, Treatment, Outcomes
Kenshi Suzuki, Ashutosh D. Wechalekar, Kihyun Kım, Chihiro Shimazaki, Jin Seok Kim, Takayuki Ikezoe, +15 more
2citations -
High complete response rates, low dropout rate, and low-grade toxicities in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) receiving GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 DLBCL cohort
Joost S.P. Vermaat, Pim G. N. J. Mutsaers, Sébastien Anguille, Maria Theresa Kuipers, Évelyne Willems, Tim J. A. Dekker, +13 more
2citations -
Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
Hartmut Goldschmidt, Uta Bertsch, Ema Požek, Axel Benner, Roland R. Fenk, Britta Besemer, +26 more
1citations
11 results